TY - JOUR
T1 - Repeating Vertebral Fracture Assessment
T2 - 2019 ISCD Official Position
AU - Borges, Joao Lindolfo Cunha
AU - Sousa da Silva, Marina
AU - Ward, Robert J.
AU - Diemer, Kathryn M.
AU - Yeap, Swan S.
AU - Lewiecki, E. Michael
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Vertebral fracture (VF) is the most common type of osteoporotic fracture. VFs are associated with a decline in quality of life and high morbidity and mortality. The presence of a VF is a significant risk factor for developing another fracture; however, most VFs are not clinically recognized and diagnosed. Vertebral fracture assessment by dual-energy X-ray absorptiometry is a low cost, low radiation, convenient, and reliable method to identify VFs. The finding of a previously unrecognized VF may change the assessment of fracture risk, diagnostic classification, and treatment strategies. Vertebral fracture assessment or radiographic lateral spine imaging should be repeated in patients with continued high risk for fracture (e.g., historical height loss >4 cm [>1.5 inches], self-reported but undocumented vertebral fracture, or glucocorticoid therapy equivalent to ≥5 mg of prednisone or equivalent per day for greater than or equal to 3 months).
AB - Vertebral fracture (VF) is the most common type of osteoporotic fracture. VFs are associated with a decline in quality of life and high morbidity and mortality. The presence of a VF is a significant risk factor for developing another fracture; however, most VFs are not clinically recognized and diagnosed. Vertebral fracture assessment by dual-energy X-ray absorptiometry is a low cost, low radiation, convenient, and reliable method to identify VFs. The finding of a previously unrecognized VF may change the assessment of fracture risk, diagnostic classification, and treatment strategies. Vertebral fracture assessment or radiographic lateral spine imaging should be repeated in patients with continued high risk for fracture (e.g., historical height loss >4 cm [>1.5 inches], self-reported but undocumented vertebral fracture, or glucocorticoid therapy equivalent to ≥5 mg of prednisone or equivalent per day for greater than or equal to 3 months).
KW - DXA
KW - Fracture
KW - Monitor
KW - Osteoporosis
KW - VFA
UR - http://www.scopus.com/inward/record.url?scp=85069882506&partnerID=8YFLogxK
U2 - 10.1016/j.jocd.2019.07.005
DO - 10.1016/j.jocd.2019.07.005
M3 - Review article
C2 - 31375350
AN - SCOPUS:85069882506
SN - 1094-6950
VL - 22
SP - 484
EP - 488
JO - Journal of Clinical Densitometry
JF - Journal of Clinical Densitometry
IS - 4
ER -